AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The Transkaryotic-Amgen case is likely not over yet.
The biotech world was buzzing this past week about the judgment against Cambridge-based Transkaryotic Therapies Inc., declaring the company had infringed on several patents held by Thousand Oaks, Calif.-based Amgen Inc. for an erythropoietin-based drug for anemia patients.
In this case, the stakes were high for Amgen, which holds the lion's share of a $4 billion worldwide market with its version of the drug, Epogen.
And after last Friday's court ruling, it would appear that hefty share of the market is safe. Consequently, Amgen's stock price was inching its way back up this past week to a 52-week high of $80.44, while TKT's stock price was trading below its …
-
- Patent precedent? Amgen versus TKT.
-
News wire article from: Asia Africa Intelligence Wire
October 30, 2004
700+ words
-
- Amgen wins TKT appeal.
-
News wire article from: Chemical Business Newsbase
August 3, 2006
700+ words
-
- TKT encouraged by US Court of Appeals Decision on patent litigation against...
-
News wire article from: Asia Africa Intelligence Wire
January 7, 2003
700+ words
-
- District Court affirms patent infringement rulings and finds that Amgen is...
-
News wire article from: Chemical Business Newsbase
October 2, 2008
700+ words
-
- TKT prevails over Kirin-Amgen in House of Lords Dynepo litigation; Amgen...
-
News wire article from: Asia Africa Intelligence Wire
October 21, 2004
700+ words
